5)
中島光好 他：臨床と研究 72（11）：2912，1995［NA-088］

6)
社内報告書（ヒト肝ミクロソーム・代謝）（DIR080082）

7)
Kadokura, T. et al.：Eur. J. Clin. Pharmacol. 64（7）：691，2008［IB-00003］

8)
Kadokura, T. et al.：Eur. J. Clin. Pharmacol. 64（6）：605，2008［IB-00004］

9)
松枝　啓 他：臨床医薬 24（7）：633，2008［IB-00006］

10)
**社内報告書（女性患者・第III相試験）（DIR150021）

11)
Hirata, T. et al.：J. Pharmacol. Sci. 104：263，2007［NA-00380］

12)
Hirata, T. et al.：Neurogastroenterol. Motil. 20（5）：557，2008［IB-00001］

13)
Hirata, T. et al.：Inflammopharmacol. 15（1）：5，2007［NA-00381］

14)
Hirata, T. et al.：J. Pharmacol. Sci. 106（2）：264，2008［NA-00388］

15)
Funatsu, T. et al.：Eur. J. Pharmacol. 573（1-3）：190，2007［NA-00390］

文献請求先・製品情報お問い合わせ先

主要文献に記載の社内報告書につきましても下記にご請求下さい。
　
**アステラス製薬株式会社　メディカルインフォメーションセンター

〒103-8411　東京都中央区日本橋本町2丁目5番1号

 0120-189-371

製造販売業者等の氏名又は名称及び住所

製造販売
アステラス製薬株式会社

東京都中央区日本橋本町2丁目5番1号
Home> Woman Topics> Astellas, "Irribow lock / Irribow OD Tablets" is efficacy and effect in diarrhea-predominant irritable bowel syndrome additional approval
<< List of May 2015
Astellas, "Irribow lock / Irribow OD Tablets" additional efficacy and effect in diarrhea-predominant irritable bowel syndrome approval
2015/05/26
Astellas Pharma Inc. ("Astellas"), the diarrhea-predominant irritable bowel syndrome therapeutic agents "Irribow (R) Tablets 2.5μg, the 5μg / Irribow (R) OD (※ 1) Tablets 2.5μg, the 5μg ": For (generic name ramosetron hydrochloride), today, we have to get approval of the Efficacy Additional information about the diarrhea-over-irritable bowel syndrome in women (※ 2).
Asurasu Pharmaceutical, in Japan, the "diarrhea-predominant irritable bowel syndrome you want put to men" as the efficacy and effect a "Irribow (R) tablet" was released in October 2008, further in January 2014, in the oral cavity collapse Tablets "Irribow (R) OD Tablets" to launch at the same indications. Efficacy With this approval was the ability to use two drugs to patients "diarrhea-type hypersensitivity syndrome", and the women of diarrhea-predominant irritable bowel syndrome.
"Irribow (R) Tablets / Irribow (R) OD Tablets", the serotonin 5-HT3 receptor antagonists that Astellas was created. Serotonin is one of the neurotransmitters, are largely related to the movement of the digestive tract. Such as serotonin released was promoted by stress, by activating the 5-HT3 receptors present in the enteric nervous and allowed to enhance the gastrointestinal motility, causing bowel movement abnormalities. Further, serotonin is released by stimulation intestinal received, by binding to 5-HT3 receptors of the afferent nerve terminals, to transmit pain to the brain.
"Irribow (R) Tablets / Irribow (R) OD Tablets" is, it is possible to selectively inhibit 5-HT3 receptor, as well as to improve the bowel movement abnormality associated with the digestive tract hyperactivity (diarrhea, defecation increased), colon it is possible to suppress the pain transmission, it is expected to improve abdominal pain and visceral hypersensitivity.
Astellas hopes to be able to provide future, a new treatment option to patients of women of diarrhea-p